news – Page 5597 – pharmaceutical daily

June 6, 2017 Off

BMS and Novartis join forces to fight cancer

Bristol-Myers Squibb and Novartis have entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen in combination with Mekinist (trametinib), as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair (MSS mCRC pMMR).

June 6, 2017 Off

CTI BioPharma prices underwritten public offering of $45M of convertible preferred stock

By Dino Mustafić

CTI BioPharma has announced the pricing of an underwritten public offering of 22,500 shares of its Series N-3 Preferred Stock, offered at a price to the public of $2,000 per share of Series N-3 Preferred Stock (the “Offering”).

June 6, 2017 Off

FDA OK’s Alkermes’s schizophrenia drug

By Dino Mustafić

The U.S. Food and Drug Administration (FDA) has approved Alkermes’s two-month Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia.

June 6, 2017 Off

European Commission approves Novartis’s leukemia drug

By Dino Mustafić

European Commission (EC) has approved the inclusion of Treatment-free Remission (TFR) data in the Novartis’s Tasigna (nilotinib) Summary of Product Characteristics (SmPC).

June 5, 2017 Off

BMS and QIAGEN join forces to study cancer using NGS technology

By Dino Mustafić

Bristol-Myers Squibb and QIAGEN have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression profiles (GEPs) as predictive or prognostic tools for use with Bristol-Myers Squibb novel immuno-oncology (I-O) therapies in cancer treatment.

June 2, 2017 Off

Novartis’s metastatic breast cancer drug improves PFS, updated results show

By Dino Mustafić

Novartis has updated findings from the Phase III MONALEESA-2 study that reinforce the efficacy and safety of Kisqali (ribociclib) plus letrozole in postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.

June 1, 2017 Off

Novartis CEO sees no need for big takeover

By Dino Mustafić

Novartis does not need a big acquisition to kick-start growth, Chief Executive Joe Jimenez told investors on Wednesday, playing down suggestions he could use proceeds from a slew of asset sales for a significant takeover.

June 1, 2017 Off

Vertex has good news for 500 Irish patients with cystic fibrosis

By Dino Mustafić

Vertex Pharmaceuticals Incorporated has reached an agreement with the Health Service Executive (HSE) in the Republic of Ireland to fund Orkambi (lumacaftor/ivacaftor).

June 1, 2017 Off

BioMarin cleared in EU for TPP1 deficiency treatment

By Dino Mustafić

BioMarin Pharmaceuticalsaid today that it got from the European Commission (EC) a grant for Brineura (cerliponase alfa), the first treatment approved in the European Union (EU) for tripeptidyl peptidase 1 (TPP1) deficiency.

June 1, 2017 Off

Alexion names several new executives

By Dino Mustafić

Alexion Pharmaceuticals has named several leading chairs to its executive leadership team that will be effective from June 5, 2017.